Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | terminated | Phase 1 | 4 | Fox Chase Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02767921 |
| sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer |
| terminated |
| Phase 1 |
| 2 |
| University of Southern CaliforniaOTHER |
| 1 |
| Nov 24, 2021 |
| clinicaltrials |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | terminated | Phase 1 / Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02792192 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants | terminated | Phase 1 / Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Oct 28, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02963051 | A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer | terminated | Phase 1 | 9 | Daniel George, MDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT03545165 | 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC | terminated | Phase 1 / Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | terminated | Phase 1 | 6 | George Washington UniversityOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer(PAZOFOS) | terminated | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT02805894 | NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma | terminated | Phase 1 / Phase 2 | 5 | NanobiotixINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT03478904 | Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer | terminated | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | May 10, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 107 | Syros PharmaceuticalsINDUSTRY | 3 | Mar 9, 2021 | clinicaltrials |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | terminated | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT03162562 | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | terminated | Phase 1 | 10 | CanariaBio Inc.INDUSTRY | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00757757 | A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases | terminated | Phase 1 / Phase 2 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT00506779 | Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | terminated | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | terminated | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | Nov 6, 2020 | clinicaltrials |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 173 | Tracon Pharmaceuticals Inc.INDUSTRY | 4 | Oct 19, 2020 | clinicaltrials |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | terminated | Phase 1 | 41 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT01690468 | PTX-200 and Carboplatin in Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 12 | South Plains Oncology ConsortiumNETWORK | 1 | Aug 27, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | terminated | Phase 1 / Phase 2 | 1 | Baylor College of MedicineOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02911467 | Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer(MR) | terminated | Phase 1 | 8 | Rahul AggarwalOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 16, 2020 | clinicaltrials |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | terminated | Phase 1 | 5 | University of UtahOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer | terminated | Phase 1 / Phase 2 | 24 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT02317302 | FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer | terminated | Phase 1 | 48 | Washington University School of MedicineOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 8, 2022source: clinicaltrials